Effectiveness of DAA Treatment for HCV in Patients With HCC Effectiveness of DAA Treatment for HCV in Patients With HCC

Is virologic reponse to direct-acting antivirals as robust in HCV patients with hepatocellular carcinoma as in those without?Alimentary Pharmacology &Therapeutics
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Related Links:

Publication date: Available online 6 April 2020Source: Journal of Geriatric OncologyAuthor(s): Sukeshi Patel Arora, Snegha Ananth, Norma Ketchum, Jonathan Gelfond, Joel Michalek, Devalingam Mahalingam
Source: Journal of Geriatric Oncology - Category: Cancer & Oncology Source Type: research
Source: Annals of Surgical Oncology - Category: Cancer & Oncology Source Type: research
Conclusion Semi-quantitative F-18 FDG PET parameters (SUVmax, MTV and T/L) were found to be significantly correlated with Fuhrman grade in patients with RCC and are important markers for differentiation between low- and high-grade tumors. Furthermore, forced diuresis had no incremental value in characterization of primary RCC lesions.
Source: Nuclear Medicine Communications - Category: Nuclear Medicine Tags: Original Articles Source Type: research
Source: OncoTargets and Therapy - Category: Cancer & Oncology Tags: OncoTargets and Therapy Source Type: research
Source: OncoTargets and Therapy - Category: Cancer & Oncology Tags: OncoTargets and Therapy Source Type: research
Conclusions: The association of sorafenib does not prolong survival nor delay progression in patients treated with radioembolization. Liver toxicity does not differ among the two therapeutic schemes.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
ConclusionsUsing both in vitro and in vivo approaches, we described the profound role of theADAMTSL3 andPTEN genes. This study indicates novel candidate targets for use in HCC treatment and therapy.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
Purpose of review The available vaccine and therapies against hepatitis B virus (HBV) rarely eliminate chronic infection with the virus. High mortality resulting from complicating cirrhosis and hepatocellular carcinoma makes improving anti-HBV therapy an important priority. Recent advances with using gene therapy to counter HBV have potential and are the focus of this review. Recent findings The stable replication-competent HBV intermediate comprising covalently closed circular DNA (cccDNA) is the template for expression of all viral genes. Inactivating cccDNA has thus been a focus of research aimed at achieving cure ...
Source: Current Opinion in HIV and AIDS - Category: Infectious Diseases Tags: HIV AND HEPATITIS B CURE: Edited by Sharon R. Lewin and Peter A. Revill Source Type: research
This article is protected by copyright. All rights reserved
Source: Biotechnology and Applied Biochemistry - Category: Biochemistry Authors: Tags: Original Article Source Type: research
Hepatocellular carcinoma (HCC) constitutes 0.5% of childhood malignancies and exhibits poor prognosis. Complete tumor extirpation either by partial liver resection (LR) or liver transplantation (LT) is the only curative treatment. Due to the poor initial outcomes of LT, LR has remained the mainstay of treatment for all but select children fulfilling the Milan criteria (originally designed for adults).
Source: Journal of the American College of Surgeons - Category: Surgery Authors: Tags: Original Scientific Article Source Type: research
More News: Cancer & Oncology | Carcinoma | Drugs & Pharmacology | Gastroenterology | Health | Hepatocellular Carcinoma | Liver Cancer | Virology